Calcitonin GeneRelated Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
Jes Olesen, M.D., Hans-Christoph Diener, M.D., Ingo W. Husstedt, M.D., Peter J. Goadsby, M.D., David Hall, Ph.D., Ulrich Meier, Ph.D., Stephane Pollentier, M.D., Lynna M. Lesko, M.D., for the BIBN 4096 BS Clinical Proof of Concept Study Group
Background Calcitonin generelated peptide (CGRP) mayhave a causative role in migraine. We therefore hypothesizedthat a CGRP-receptor antagonist might be effective in the treatmentof migraine attacks.
Methods In an international, multicenter, double-blind, randomizedclinical trial of BIBN 4096 BS, a highly specific and potentnonpeptide CGRP-receptor antagonist, 126 patients with migrainereceived one of the following: placebo or 0.25, 0.5, 1, 2.5,5, or 10 mg of BIBN 4096 BS intravenously over a period of 10minutes. A group-sequential adaptive treatment-assignment designwas used to minimize the number of patients exposed.
Results The 2.5-mg dose was selected, with a response rate of66 percent, as compared with 27 percent for placebo (P=0.001).The BIBN 4096 BS group as a whole had a response rate of 60percent. Significant superiority over placebo was also observedwith respect to most secondary end points: the pain-free rateat 2 hours; the rate of sustained response over a period of24 hours; the rate of recurrence of headache; improvement innausea, photophobia, phonophobia, and functional capacity; andthe time to meaningful relief. An effect was apparent after30 minutes and increased over the next few hours. The overallrate of adverse events was 25 percent after the 2.5-mg doseof the drug and 20 percent for the BIBN 4096 BS group as a whole,as compared with 12 percent for placebo. The most frequent sideeffect was paresthesia. There were no serious adverse events.
Conclusions The CGRP antagonist BIBN 4096 BS was effective intreating acute attacks of migraine.
Source Information
From the Department of Neurology, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark (J.O.); the Department of Neurology, University of Essen, Essen, Germany (H.-C.D.); the Department of Neurology, University Hospital, Münster, Germany (I.W.H.); the Institute of Neurology, London (P.J.G.); Boehringer Ingelheim Pharmaceuticals, Ridgefield, Conn. (D.H., L.M.L.); and Boehringer Ingelheim Pharma, Ingelheim, Germany (U.M., S.P.).
Address reprint requests to Dr. Olsen at the University of Copenhagen, Department of Neurology, Glostrup Hospital, 2600 Glostrup, Copenhagen, Denmark, or at jeol{at}glostruphosp.kbhamt.dk.
Sixt, M.-L., Messlinger, K., Fischer, M. J. M.
(2009). Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain
132: 3134-3141
[Abstract][Full Text]
Charbit, A. R., Akerman, S., Holland, P. R., Goadsby, P. J.
(2009). Neurons of the Dopaminergic/Calcitonin Gene-Related Peptide A11 Cell Group Modulate Neuronal Firing in the Trigeminocervical Complex: An Electrophysiological and Immunohistochemical Study. J. Neurosci.
29: 12532-12541
[Abstract][Full Text]
Connor, K. M., Shapiro, R. E., Diener, H. -C., Lucas, S., Kost, J., Fan, X., Fei, K., Assaid, C., Lines, C., Ho, T. W.
(2009). Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology
73: 970-977
[Abstract][Full Text]
Wang, Z., Ma, W., Chabot, J.-G., Quirion, R.
(2009). Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia. FASEB J.
23: 2576-2586
[Abstract][Full Text]
Recober, A., Kuburas, A., Zhang, Z., Wemmie, J. A., Anderson, M. G., Russo, A. F.
(2009). Role of Calcitonin Gene-Related Peptide in Light-Aversive Behavior: Implications for Migraine. J. Neurosci.
29: 8798-8804
[Abstract][Full Text]
Bailey, D. M., Taudorf, S., Berg, R. M.G., Jensen, L. T., Lundby, C., Evans, K. A., James, P. E., Pedersen, B. K., Moller, K.
(2009). Transcerebral Exchange Kinetics of Nitrite and Calcitonin Gene-Related Peptide in Acute Mountain Sickness: Evidence Against Trigeminovascular Activation?. Stroke
40: 2205-2208
[Abstract][Full Text]
Cady, R. K.
(2009). The Future of Migraine: Beyond Just Another Pill. Mayo Clin Proc.
84: 397-399
[Full Text]
Meng, J., Ovsepian, S. V., Wang, J., Pickering, M., Sasse, A., Aoki, K. R., Lawrence, G. W., Dolly, J. O.
(2009). Activation of TRPV1 Mediates Calcitonin Gene-Related Peptide Release, Which Excites Trigeminal Sensory Neurons and Is Attenuated by a Retargeted Botulinum Toxin with Anti-Nociceptive Potential. J. Neurosci.
29: 4981-4992
[Abstract][Full Text]
Ambalavanar, R., Dessem, D.
(2009). Emerging Peripheral Receptor Targets for Deep-tissue Craniofacial Pain Therapies. JDR
88: 201-211
[Abstract][Full Text]
Regan, C. P., Stump, G. L., Kane, S. A., Lynch, J. J. Jr.
(2009). Calcitonin Gene-Related Peptide Receptor Antagonism Does Not Affect the Severity of Myocardial Ischemia during Atrial Pacing in Dogs with Coronary Artery Stenosis. J. Pharmacol. Exp. Ther.
328: 571-578
[Abstract][Full Text]
Goadsby, P. J.
(2009). The vascular theory of migraine--a great story wrecked by the facts. Brain
132: 6-7
[Full Text]
Hansen, J. M., Thomsen, L. L., Olesen, J., Ashina, M.
(2008). Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology
71: 841-847
[Abstract][Full Text]
Schoonman, G. G., van der Grond, J., Kortmann, C., van der Geest, R. J., Terwindt, G. M., Ferrari, M. D.
(2008). Migraine headache is not associated with cerebral or meningeal vasodilatation--a 3T magnetic resonance angiography study. Brain
131: 2192-2200
[Abstract][Full Text]
Simonetti, M., Giniatullin, R., Fabbretti, E.
(2008). Mechanisms Mediating the Enhanced Gene Transcription of P2X3 Receptor by Calcitonin Gene-related Peptide in Trigeminal Sensory Neurons. J. Biol. Chem.
283: 18743-18752
[Abstract][Full Text]
Qin, N., Neeper, M. P., Liu, Y., Hutchinson, T. L., Lubin, M. L., Flores, C. M.
(2008). TRPV2 Is Activated by Cannabidiol and Mediates CGRP Release in Cultured Rat Dorsal Root Ganglion Neurons. J. Neurosci.
28: 6231-6238
[Abstract][Full Text]
Goadsby, P. J.
(2008). Calcitonin gene-related peptide (CGRP) antagonists and migraine: Is this a new era?. Neurology
70: 1300-1301
[Full Text]
Ho, T. W., Mannix, L. K., Fan, X., Assaid, C., Furtek, C., Jones, C. J., Lines, C. R., Rapoport, A. M., On behalf of the MK-0974 Protocol 004 study group,
(2008). Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology
70: 1304-1312
[Abstract][Full Text]
Starr, A., Graepel, R., Keeble, J., Schmidhuber, S., Clark, N., Grant, A., Shah, A. M., Brain, S. D.
(2008). A reactive oxygen species-mediated component in neurogenic vasodilatation. Cardiovasc Res
78: 139-147
[Abstract][Full Text]
Bucelli, R. C., Gonsiorek, E. A., Kim, W.-Y., Bruun, D., Rabin, R. A., Higgins, D., Lein, P. J.
(2008). Statins Decrease Expression of the Proinflammatory Neuropeptides Calcitonin Gene-Related Peptide and Substance P in Sensory Neurons. J. Pharmacol. Exp. Ther.
324: 1172-1180
[Abstract][Full Text]
Park, K.-Y., Russo, A. F.
(2008). Control of the Calcitonin Gene-related Peptide Enhancer by Upstream Stimulatory Factor in Trigeminal Ganglion Neurons. J. Biol. Chem.
283: 5441-5451
[Abstract][Full Text]
Salvatore, C. A., Hershey, J. C., Corcoran, H. A., Fay, J. F., Johnston, V. K., Moore, E. L., Mosser, S. D., Burgey, C. S., Paone, D. V., Shaw, A. W., Graham, S. L., Vacca, J. P., Williams, T. M., Koblan, K. S., Kane, S. A.
(2008). Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. J. Pharmacol. Exp. Ther.
324: 416-421
[Abstract][Full Text]
D'Arco, M., Giniatullin, R., Simonetti, M., Fabbro, A., Nair, A., Nistri, A., Fabbretti, E.
(2007). Neutralization of Nerve Growth Factor Induces Plasticity of ATP-Sensitive P2X3 Receptors of Nociceptive Trigeminal Ganglion Neurons. J. Neurosci.
27: 8190-8201
[Abstract][Full Text]
Clifton, M. S., Hoy, J. J., Chang, J., Idumalla, P. S., Fakhruddin, H., Grady, E. F., Dada, S., Corvera, C. U., Bhargava, A.
(2007). Role of calcitonin receptor-like receptor in colonic motility and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol.
293: G36-G44
[Abstract][Full Text]
Bigal, M. E., Lipton, R. B., Holland, P. R., Goadsby, P. J.
(2007). Obesity, migraine, and chronic migraine: Possible mechanisms of interaction. Neurology
68: 1851-1861
[Abstract][Full Text]
Moskowitz, M. A.
(2007). The 2006 Thomas Willis Lecture: The Adventures of a Translational Researcher in Stroke and Migraine. Stroke
38: 1645-1651
[Full Text]
Cottrell, G. S., Padilla, B., Pikios, S., Roosterman, D., Steinhoff, M., Grady, E. F., Bunnett, N. W.
(2007). Post-endocytic Sorting of Calcitonin Receptor-like Receptor and Receptor Activity-modifying Protein 1. J. Biol. Chem.
282: 12260-12271
[Abstract][Full Text]
Zhang, Z., Winborn, C. S., Marquez de Prado, B., Russo, A. F.
(2007). Sensitization of Calcitonin Gene-Related Peptide Receptors by Receptor Activity-Modifying Protein-1 in the Trigeminal Ganglion. J. Neurosci.
27: 2693-2703
[Abstract][Full Text]
Olesen, J., Baker, M. G, Freund, T., di Luca, M., Mendlewicz, J., Ragan, I., Westphal, M.
(2006). Consensus document on European brain research. J. Neurol. Neurosurg. Psychiatry
77: i1-i49
[Abstract][Full Text]
Fabbretti, E., D'Arco, M., Fabbro, A., Simonetti, M., Nistri, A., Giniatullin, R.
(2006). Delayed upregulation of ATP P2X3 receptors of trigeminal sensory neurons by calcitonin gene-related peptide.. J. Neurosci.
26: 6163-6171
[Abstract][Full Text]
Strassman, A. M., Levy, D.
(2006). Response Properties of Dural Nociceptors in Relation to Headache. J. Neurophysiol.
95: 1298-1306
[Abstract][Full Text]
Goadsby, P. J
(2006). Recent advances in the diagnosis and management of migraine. BMJ
332: 25-29
[Full Text]
Holland, P. R., Akerman, S., Goadsby, P. J.
(2005). Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigeminovascular Nociception. J. Pharmacol. Exp. Ther.
315: 1380-1385
[Abstract][Full Text]
Goadsby, P. J.
(2005). Advances in the understanding of headache. Br Med Bull
73-74: 83-92
[Abstract][Full Text]
Peroutka, S. J.
(2005). NEUROGENIC INFLAMMATION AND MIGRAINE: IMPLICATIONS FOR THE THERAPEUTICS. Mol. Interv.
5: 304-311
[Abstract][Full Text]
Mogil, J. S., Miermeister, F., Seifert, F., Strasburg, K., Zimmermann, K., Reinold, H., Austin, J.-S., Bernardini, N., Chesler, E. J., Hofmann, H. A., Hordo, C., Messlinger, K., Nemmani, K. V. S., Rankin, A. L., Ritchie, J., Siegling, A., Smith, S. B., Sotocinal, S., Vater, A., Lehto, S. G., Klussmann, S., Quirion, R., Michaelis, M., Devor, M., Reeh, P. W.
(2005). Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc. Natl. Acad. Sci. USA
102: 12938-12943
[Abstract][Full Text]
Pietrobon, D.
(2005). Migraine: New Molecular Mechanisms. Neuroscientist
11: 373-386
[Abstract]
Akerman, S., Goadsby, P. J.
(2005). The Role of Dopamine in a Model of Trigeminovascular Nociception. J. Pharmacol. Exp. Ther.
314: 162-169
[Abstract][Full Text]
Fischer, M. J. M., Koulchitsky, S., Messlinger, K.
(2005). The Nonpeptide Calcitonin Gene-Related Peptide Receptor Antagonist BIBN4096BS Lowers the Activity of Neurons with Meningeal Input in the Rat Spinal Trigeminal Nucleus. J. Neurosci.
25: 5877-5883
[Abstract][Full Text]
Waeber, C., Moskowitz, M. A.
(2005). Migraine as an inflammatory disorder. Neurology
64: S9-S15
[Full Text]
Viney, T. J., Schmidt, T. W., Gierasch, W., Sattar, A. W., Yaggie, R. E., Kuburas, A., Quinn, J. P., Coulson, J. M., Russo, A. F.
(2004). Regulation of the Cell-specific Calcitonin/Calcitonin Gene-related Peptide Enhancer by USF and the Foxa2 Forkhead Protein. J. Biol. Chem.
279: 49948-49955
[Abstract][Full Text]